Scholarlink

Background <p>Although clinical trials have demonstrated the efficacy and safety of abrocitinib in atopic dermatitis, there remains a lack of comprehensive long-term real-world studies across diverse patient populations.</p> Objective <p>We aimed to characterize long-term treatment responses and adverse events of abrocitinib in adults with moderate-to-severe atopic dermatitis in real-world daily practice.</p> Methods <p>We conducted a retrospective observational study of adults with moderate-to-severe atopic dermatitis who were treated with abrocitinib between 1 January, 2022 and 1 January, 2025 at a multi-site hospital system. Final follow-up was defined as each patient’s last documented clinic visit before 1 January, 2025. Primary outcomes were changes in clinical severity scores from baseline to the final follow-up. Secondary outcomes included 1-year clinical response rates, laboratory trends, adverse events, and treatment discontinuations.</p> Results <p>We identified 50 adults with moderate-to-severe atopic dermatitis (mean age 40 ± 14 years; 56% female) who had been treated with abrocitinib. Most (96%) had not responded to prior systemic therapies, including dupilumab (80%) and prednisone (36%). Clinical response improved over time: at 12–24 weeks (<i>n</i> = 33), 43.5% achieved an improvement of 75% or more in the Eczema Area and Severity Index (EASI-75) and 42.9% achieved an Investigator’s Global Assessment (IGA) 0/1; by 36–48 weeks (<i>n</i> = 18), these rates rose to 53.9% and 45.5%, respectively. After 1 year (<i>n</i> = 29), 52.6% maintained EASI-75 and 56.5% achieved IGA 0/1. Final follow-up showed significant reductions from baseline in IGA (− 48.5%), body surface area (− 60.3%), and EASI (− 58.6%) [all <i>p</i> &lt; 0.0001]. Adverse events were mild, the most common were acne (8%) and nausea (6%).</p> Conclusions <p>In our real-world study, adults with moderate-to-severe atopic dermatitis treated with abrocitinib had a progressive sustained clinical improvement across various races, ages, doses, disease onsets, atopic comorbidities, and body mass index ranges.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Long-Term Real-World Evaluation of Abrocitinib in Moderate-to-Severe Atopic Dermatitis Across a Diverse Patient Population in a Multi-site Hospital System

  • 期刊论文

  • 发表日期：

    2026年1月27日

查看全文
  • Megan Lau,
  • Joseph Largen,
  • Jasmine Levine,
  • Ester Del Duca,
  • Lillian Mo,
  • Kathryn Jayne Tan,
  • Daniel Liu,
  • Akbobek Amangeldiyeva,
  • Joel Correa da Rosa,
  • Princess Edemobi,
  • Benjamin Ungar,
  • Emma Guttman-Yassky

摘要

Background

Although clinical trials have demonstrated the efficacy and safety of abrocitinib in atopic dermatitis, there remains a lack of comprehensive long-term real-world studies across diverse patient populations.

Objective

We aimed to characterize long-term treatment responses and adverse events of abrocitinib in adults with moderate-to-severe atopic dermatitis in real-world daily practice.

Methods

We conducted a retrospective observational study of adults with moderate-to-severe atopic dermatitis who were treated with abrocitinib between 1 January, 2022 and 1 January, 2025 at a multi-site hospital system. Final follow-up was defined as each patient’s last documented clinic visit before 1 January, 2025. Primary outcomes were changes in clinical severity scores from baseline to the final follow-up. Secondary outcomes included 1-year clinical response rates, laboratory trends, adverse events, and treatment discontinuations.

Results

We identified 50 adults with moderate-to-severe atopic dermatitis (mean age 40 ± 14 years; 56% female) who had been treated with abrocitinib. Most (96%) had not responded to prior systemic therapies, including dupilumab (80%) and prednisone (36%). Clinical response improved over time: at 12–24 weeks (n = 33), 43.5% achieved an improvement of 75% or more in the Eczema Area and Severity Index (EASI-75) and 42.9% achieved an Investigator’s Global Assessment (IGA) 0/1; by 36–48 weeks (n = 18), these rates rose to 53.9% and 45.5%, respectively. After 1 year (n = 29), 52.6% maintained EASI-75 and 56.5% achieved IGA 0/1. Final follow-up showed significant reductions from baseline in IGA (− 48.5%), body surface area (− 60.3%), and EASI (− 58.6%) [all p < 0.0001]. Adverse events were mild, the most common were acne (8%) and nausea (6%).

Conclusions

In our real-world study, adults with moderate-to-severe atopic dermatitis treated with abrocitinib had a progressive sustained clinical improvement across various races, ages, doses, disease onsets, atopic comorbidities, and body mass index ranges.